Last reviewed · How we verify
NCT06938139
Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy
trial testing None-placebo in Gastric Adenocarcinoma in 90,000 participants. Participants enrolled and being followed up; not accepting new ones.
30 April 2025
Quick facts
| Lead sponsor | Fujian Medical University |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 90,000 |
| Start date | 1 March 2025 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- None-placebo — full drug profile →
Conditions studied
- Gastric Adenocarcinoma — all drugs for Gastric Adenocarcinoma →
- Surgery, Laparoscopic — all drugs for Surgery, Laparoscopic →
Sponsor
Fujian Medical University
Who can join
Eligibility, any sex, with Gastric Adenocarcinoma or Surgery, Laparoscopic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Benchmark-MISGC study was a large-scale retrospective observational study launched by the China Gastric Cancer Surgical Union, aiming to establish the benchmarks of the short- and long-term outcomes for gastric cancer patients who underwent minimal invasive gastrectomy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06938139
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of None-placebo
Trials testing the same drug.
- NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers · not yet recruiting
- NCT07416981 — Urinary CTGF in Benign Prostatic Obstruction · not yet recruiting
- NCT07183878 — Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY · NA · recruiting
- NCT07194330 — External Iliac Artery Endofibrosis in Cycling · active not recruiting
- NCT06824493 — Orthodontic Treatment on Oral Microbiota and Salivary Proteins · not yet recruiting
Other recruiting trials for Gastric Adenocarcinoma
Currently open trials in the same condition.
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
- NCT07522320 — Costs of Opportunistic Upper Gastrointestinal Endoscopy and the Economic Burden of Gastric Cancer Management · active not recruiting
- NCT07182149 — A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors · Phase 1 · recruiting
- NCT07001748 — Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G · Phase 2, PHASE3 · recruiting
- NCT07103668 — A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients · Phase 3 · recruiting
Other Fujian Medical University trials
Trials by the same sponsor.
- NCT07314203 — Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastr · Phase 3 · not yet recruiting
- NCT07491263 — Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Le · Phase 1 · not yet recruiting
- NCT07275034 — A Virtual Reality-Based Horticultural Planting Program for Elderly With Subthreshold Depression · NA · not yet recruiting
- NCT07383909 — Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery · NA · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06938139 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University
- Last refreshed: 22 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06938139.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing